AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q3 2019 Earnings Presentation

24 slides from AMAG Pharmaceuticals's earnings presentation, Nov 1, 2019

  1. Slide 1: AMAG Pharmaceuticals Third Quarter 2019 Financial Results

    AMAG Pharmaceuticals Third Quarter 2019 Financial Results November 1, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG

  3. Slide 3: Cautionary Disclosure Regarding AMAG's Long-term Outlook

    Cautionary Disclosure Regarding AMAG’s Long-term Outlook AMAG has made forward looking estimates of its long-term outlook, including that it will be adjusted EBITDA neutral by 2020. AMAG’s growth trajectory and expectations for adjusted EBITDA on a multi-year timeframe are based on a strategy of max

  4. Slide 4: Agenda

    Agenda 1 Q3-2019 Highlights 2 Makena FDA Advisory Committee Meeting Update 3 Vyleesi Launch Update 4 Q3 Financial Results and Guidance 5 Development Pipeline Update 6 Closing Remarks/Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 4

  5. Slide 5: Strong Key Commercial Products' Performance

    Strong Key Commercial Products’ Performance Subcutaneous Auto-injector Record Revenues & Market Share1 Quarterly Market Share2 TRx/NRx Average Market Share3 5.0% Revenues 4.5% % 63% 63% YoY: up nearly 20% 54 4.0% TRx QoQ: up more than 5% 3.5% 3.0% NRx Market share 2.5% 2.0% Q1-2019 Q2-2019 Q3-2019 1

  6. Slide 6: Makena FDA Advisory Committee Meeting Update

    Makena FDA Advisory Committee Meeting Update 6

  7. Slide 7: Makena PROLONG Update

    Makena PROLONG Update PROLONG Study Results Published (October 25) • The American Journal of Perinatology • Primary author Dr. Sean Blackwell puts results in perspective in discussion section Professional Societies Recently Updated Guidelines (October 25) • American College of Obstetricians and Gyne

  8. Slide 8: Vyleesi National Launch – September 2019

    Vyleesi National Launch – September 2019 8

  9. Slide 9: Vyleesi Launched Nationally September 2019

    Vyleesi Launched Nationally September 2019 First FDA-approved as-needed treatment option for premenopausal women1 Early experience program built demand and enhanced market knowledge ahead of launch Accelerating Approximately 125 sales professionals Engagement now targeting 15,000 HCPs Social and dig

  10. Slide 10: Early Feedback

    Early Feedback I have had 4 different providers requesting me to come by and detail Vyleesi. Those requests came from no access offices. Vyleesi sales rep WOMEN’S HEALTH: VYLEESI © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 10

  11. Slide 11: Encouraging Early Launch Metrics

    Encouraging Early Launch Metrics Early metrics through one month post launch 12.6M 120k+ 1,300+ 1 women 40.7M symptom prescribers have been impressions checkers 3,000+ reached completed prescriptions1 What you can expect post first full quarter when we report 4Q19 Early Digital & formulary Number of

  12. Slide 12: Financial Overview

    Financial Overview 12

  13. Slide 13: Sequential Quarter Revenue Summary

    Sequential Quarter Revenue Summary • Makena SC auto-injector: ($M) Q3-2019 Q2-2019 – Revenue stable at ~$40M per quarter and in-line with company expectations Makena subcutaneous (SC) $41.3 $41.0 auto-injector Makena intramuscular (IM) – (7.0) (10.0) branded and generic Total Makena $34.3 $31.0 Fera

  14. Slide 14: Year-over-Year Quarterly Revenue Summary

    Year-over-Year Quarterly Revenue Summary Third quarter 2019 financial results ($M) Q3-2019 Q3-2018 • Makena IM year-over-year decrease related to: Makena subcutaneous (SC) $41.3 $39.2 ▪ Generic entrants in July 2018 auto-injector ▪ Third-party manufacturing challenges Makena intramuscular (IM) – (7.

  15. Slide 15: Operating Expense and Income/Loss Summary

    Operating Expense and Income/Loss Summary Third quarter 2019 financial results Three Months Ended September 30, • Decline in CoPS primarily related to: – ($M) 2019 2018 Decrease in amortization expense associated with Makena IM intangible asset Amortization of intangible assets $4.2 $30.9 – Direct C

  16. Slide 16: 2019 Financial Guidance

    2019 Financial Guidance 1 Updated 2019 Guidance (November) Previous 2019 Guidance (August) ($M) Low Mid High Low Mid High Total revenue $320 $325 $330 $325 $340 $355 GAAP operating loss ($278) ($273) ($268) ($286) ($281) ($276) Non-GAAP adjusted EBITDA ($75) ($70) ($65) ($85) ($80) ($75) 1 See slide

  17. Slide 17: Development Pipeline Update

    Development Pipeline Update 17

  18. Slide 18: Development Pipeline is Progressing

    Development Pipeline is Progressing Commercial products help fund development programs Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia Anticoagulant reversal agent Ciraparantag (potential for orphan drug designation) HEMATOLOGY Treatment to reduce rec

  19. Slide 19: Focus: Looking Ahead

    Focus: Looking Ahead Makena Continue enrollment and additional SC Auto- Maintain strong market share AMAG-423 site initiations, including EU injector FDA AdComm follow up IDE submission (Perosphere Technologies) Vyleesi Continue to drive successful launch Ciraparantag Complete healthy volunteer stud

  20. Slide 20: AMAG Pharmaceuticals Third Quarter 2019 Financial Results Q&A

    AMAG Pharmaceuticals Third Quarter 2019 Financial Results Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 20

  21. Slide 21: Appendix

    Appendix 21

  22. Slide 22: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results ($M) Q3-2019 Q3-2018 9-Mos. 2019 9-Mos. 2018 GAAP operating income ($18.0) ($19.3) ($251.6) ($28.2) Depreciation and intangible asset amortization 4.8 31.4 13.9 146.0 Non-cash inventory step-up adjustments -- 0.4 -- 3.6 Stock-based compensation 5.

  23. Slide 23: Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance 2019 Financial Guidance ($M) Revised Guidance Previous Guidance Operating loss ($278) – ($268) ($286) – ($276) Depreciation & intangible asset amortization 20 18 Stock-based compensation 19 19 Acquired IPR&D 75 75 Restructuring 7 7 Asset imp

  24. Slide 24: AMAG Pharmaceuticals Third Quarter 2019 Financial Results

    AMAG Pharmaceuticals Third Quarter 2019 Financial Results November 1, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 24

AMAG Pharmaceuticals — Q3 2019 Earnings Presentation on 6ix